Engflag

Fosfomicina Doc

Quick links to important sections

Fosfomicina Doc

Fosfomicina Doc_EN

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal

Treatment option: Infection, Infection,Urinary Tract, Acute Bacterial Cystitis, Fits, Infection Prophylaxis, Urethritis, Cystitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fosfomicina Doc

Property Description
Active ingredient Fosfomycin (as the trometamol salt)
Form Granules for oral solution
Pharmacological Class Antibiotic; Phosphono Compound
Common Use Anti-infective for susceptible bacteria
Origin Synthetic

What Type of Medicine is Fosfomicina Doc?

Fosfomicina Doc is a pharmaceutical preparation containing the synthetic, broad-spectrum antibiotic known as Fosfomycin. It is structurally classified within the distinct group of phosphono compounds, which differentiates it from the beta-lactam and aminoglycoside antibiotic classes.

This single-product formulation typically utilizes the trometamol salt of Fosfomycin, a specific chemical structure chosen to optimize the drug’s absorption when taken orally. This synthetic origin and unique chemical profile contribute to its reliable activity profile against a wide array of microbial targets.

Composition and Presentation of Fosfomicina Doc

The medication is supplied as granules for oral solution, a powdered preparation intended to be fully dissolved in water immediately prior to ingestion. This dosage form facilitates the drug's intended oral route of administration, enabling systemic delivery of the active agent throughout the body.

As a single agent, the preparation consists of the active antibacterial substance, Fosfomycin trometamol, along with essential water-soluble granular excipients. The use of the trometamol salt is a compositional feature designed to enhance the efficient transfer of the drug from the gastrointestinal tract into the bloodstream.

General Therapeutic Purpose of Fosfomycin

The fundamental purpose of Fosfomycin is its role as an anti-infective for addressing bacterial proliferation susceptible to its action. Its clinically recognized broad-spectrum efficacy enables it to target and eliminate a wide range of bacterial microorganisms, including both Gram-negative and Gram-positive types. This versatile activity establishes its significance as an important therapeutic option in the management of certain bacterial infections.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Fosfomicina Doc?

Possible side effects and safety information

Official regulatory documents classify the possible adverse reactions of Fosfomycin trometamol according to the frequency with which they are observed, ranging from common to those of unknown frequency, as reported in clinical trials and post-marketing surveillance.

Adverse effects are formally grouped by the body system affected, with the most frequently reported reactions involving the Gastrointestinal disorders class. Common reactions include Diarrhoea, Nausea, Abdominal pain, and Dyspepsia. Reactions such as Vomiting, Rash, and Urticaria are generally listed as uncommon.

Serious Adverse Reactions and Safety Constraints

The medicine's regulatory profile includes the potential for rare but serious adverse reactions. These reactions are often classified as having a frequency that cannot be estimated from the available data. Documented serious events include Antibiotic-associated colitis, which may occur during or after treatment, and severe allergic reactions such as Anaphylactic shock and Angioedema.

Formal safety constraints are applied to specific patient groups. The medicine is contraindicated in individuals with known hypersensitivity to the active substance or excipients. Furthermore, the use of this drug is restricted in patients with severe renal failure, specifically those with a creatinine clearance below 10 ml/min. The label notes that the occurrence of dizziness or vertigo may influence the ability to drive or operate machinery. Concomitant administration with drugs that increase gut motility, such as metoclopramide, should be avoided as this may result in lower drug concentrations.

Overdose and Emergency Response

Overdose Scope

Property Description (Official Regulatory-Derived)
Documented Overdose Presentations Symptoms officially listed following an acute overdose include vestibular disturbances (loss of balance), impaired hearing (transient deafness), and a persistent metallic taste or general decline in taste perception. Other manifestations, primarily observed with parenteral forms, include somnolence and signs of electrolyte disturbances.
Physiological Systems Affected (as stated in label) Primarily affects the central and peripheral nervous systems (vestibular/auditory function) and fluid/electrolyte balance. Overexposure has been associated with serious illness.
Dose-Related or Exposure-Related Factors (if applicable) Risk of accumulation and increased adverse effects, including neurotoxicity, exists for patients with severe renal impairment due to reduced clearance of the drug.
Population-Specific Overdose Notes (if applicable) Patients with severely compromised kidney function require heightened consideration during overexposure due to the drug's dependence on renal elimination.
Emergency-Response Statements (as written in official documents) Seek immediate medical attention and contact a poison control center or emergency services. In the event of signs of collapse, difficulty breathing, or inability to be awakened, emergency services must be called immediately.
When Immediate Medical Help Is Required (label-derived phrasing only) Urgent medical evaluation is required for overexposure, particularly if manifestations such as collapse, seizure, or signs of severe hypersensitivity are present.

Overdose Classifications (High-Level)

Property Description (Official Regulatory-Derived)
Severity Classification (as defined in official documents) Overexposure has been officially classified as potentially resulting in serious illness or death.
Regulatory Basis (EMA / FDA / etc.) Information is derived from the Overdose sections of global regulatory prescribing information and monographs.
Overdose-Context Constraints (as defined in official documents) No specific antidote is known for Fosfomycin overexposure.

Resulting Overdose Structure

Official Overdose Statements:

  • Documented overdose manifestations include transient disturbances in vestibular function and hearing, alongside an altered sense of taste.
  • No specific antidote is known, leading to a management strategy focused on symptomatic and supportive treatment.
  • Patients must be monitored, especially for plasma/serum electrolyte status, with rehydration and forced diuresis recommended to promote urinary drug elimination.

Connection to the overall overdose profile: Regulatory documents define this drug's overexposure profile by specifying key neuro-sensory and balance disturbances. The required emergency action is to seek immediate medical attention, as mandated by regulatory authorities, with management procedures limited to symptomatic and supportive measures given the absence of a specific neutralizing agent.

Therapeutic Uses of Fosfomicina Doc

Main Therapeutic Uses

Fosfomicina Doc is an antibiotic primarily used for the treatment of uncomplicated urinary tract infections (UTIs). It is specifically indicated for conditions where bacteria have entered the bladder or lower urinary tract, leading to inflammation and discomfort.

The most common conditions treated include:

  • Acute Bacterial Cystitis: Sudden inflammation of the bladder caused by a bacterial infection.
  • Recurrent Cystitis: Prevention or treatment of acute episodes in patients who experience frequent urinary tract infections.
  • Non-Specific Bacterial Urethritis: Inflammation of the urethra caused by susceptible bacteria.

Mechanism of Action and Benefits

As a broad-spectrum antibiotic, this medication works by interfering with the cell wall synthesis of various bacteria. This action prevents the bacteria from multiplying and allows the body's immune system to clear the infection.

Targeting Common Pathogens

Fosfomicina Doc is effective against a wide range of Gram-positive and Gram-negative bacteria that typically cause urinary infections, including Escherichia coli, which is responsible for the majority of these cases. Its targeted action in the urinary tract is a primary benefit, as the medication reaches high concentrations in the urine shortly after administration.

Key Advantages

  • Localized Concentration: The active ingredient remains effective within the bladder for an extended period, maintaining levels necessary to eliminate pathogens.
  • Bactericidal Activity: It actively kills bacteria rather than just inhibiting their growth, which helps in the rapid resolution of symptoms such as burning during urination or frequent urges to void.
  • Efficacy Against Resistant Strains: Due to its unique chemical structure, it may remain effective against certain bacterial strains that have developed resistance to other common antibiotic classes.

Eligibility and Restrictions for Use

Who can and cannot use Fosfomicina Doc?

The population eligibility for Fosfomicina Doc (Fosfomycin trometamol) is strictly defined by regulatory guidelines and is classified into approved, restricted, and contraindicated groups.

Populations Permitted or Restricted

Classification Eligibility Status
Approved Age and Sex Groups Adult women and female adolescents ge 12 years of age are the primarily eligible population for the uncomplicated cystitis indication.
Geriatric Use No specific dose adjustment is required for older adults with normal renal function.
Pregnancy and Lactation Use is restricted; it should only be administered if clearly necessary, as the substance is excreted in human milk.
Male Patients The medicine is not indicated for urinary tract infection treatment in males, as these infections are typically considered complicated.

Contraindications and Non-Eligibility

Classification Restriction Basis
Absolute Contraindication Patients with known hypersensitivity or allergy to fosfomycin trometamol or any of the excipients must not use the medicine.
Organ Function Use is contraindicated in patients with severe renal impairment (creatinine clearance < 10 mL/min) or those undergoing haemodialysis.
Pediatric Use Safety and effectiveness have not been established for children under 12 years of age, and its use is not recommended in this group.

What should I know about interactions with other medicines?

The official regulatory profile for Fosfomycin trometamol identifies several interaction patterns that affect the drug’s systemic exposure and pharmacodynamic activity.

Pharmacokinetic and Timing Constraints

Co-administration with agents that increase gastrointestinal motility, such as Metoclopramide, is officially documented to lower the serum concentrations and urinary excretion of Fosfomycin. Due to this reduction in overall drug exposure, co-administration of Metoclopramide and other pro-motility products should be avoided. The concurrent use of Cimetidine has been documented to not affect the pharmacokinetics of Fosfomycin.

Food intake delays the absorption of the medicine, resulting in a slight decrease in peak plasma levels and urinary concentrations. To counteract this, official guidance recommends separating administration by approximately two to three hours after meals, or taking it on an empty stomach.

Pharmacodynamic and Restriction Notes

Fosfomycin is an antibiotic and has been associated with a potential for increased oral anticoagulant activity (e.g., changes in INR) when used concomitantly with agents like Warfarin. Additionally, co-administration with Live Bacterial Vaccines (such as the oral cholera vaccine, live) is not recommended due to the potential for pharmacodynamic antagonism, which may compromise vaccine effectiveness.

Finally, the drug’s profile notes that Renal Insufficiency is a physiological condition that significantly decreases the excretion and clearance of Fosfomycin.

Mechanism of Action

Irreversible Blockade of Initial Cell Wall Synthesis

Fosfomycin's mechanism centers on the irreversible inhibition of the bacterial enzyme MurA (UDP-N-acetylglucosamine 3-enolpyruvyltransferase). The drug achieves this by forming a stable, covalent bond with a specific cysteine residue within the enzyme's active site. MurA catalyzes the crucial first step in the formation of peptidoglycan, the polymer required for the rigid bacterial cell wall. By permanently inactivating MurA, Fosfomycin immediately stops the initiation of peptidoglycan synthesis, thereby blocking the supply of essential cell wall building blocks.

Cascade Failure and Bactericidal Effect

The blockade of peptidoglycan precursors initiates a lethal cascade failure. Without a constant supply of these components, the bacteria cannot construct or repair its structural wall. This structural compromise leaves the bacterial cell vulnerable to high osmotic pressure from the surrounding environment, leading to rapid cell lysis (rupture) and death. This targeted, molecular action results in a core bactericidal physiological effect against susceptible organisms, achieving the necessary structural disintegration for elimination.

Dosage and Administration Information

Instruction Map: How to use Fosfomicina Doc — Administration Guidelines

This map consolidates the instructions for the administration of Fosfomycin trometamol (the active component in Fosfomicina Doc).

Administration Scope

Scope Detail Instructions
Route of administration: Oral use only, as a solution prepared from single-dose granules.
Dosing schedule: The standard regimen for acute uncomplicated cystitis in women and female adolescents is a single dose of 3 grams of fosfomycin. A two-dose regimen (3 grams per dose) is used for prophylaxis related to transrectal prostate biopsy.
Timing in relation to meals (if applicable): The dose should preferably be taken on an empty stomach to optimize drug absorption. This is typically advised as two to three hours before or after a meal.
Preparation requirements (if applicable): The entire contents of the sachet must be fully dissolved in a glass of water and the resulting solution consumed immediately after preparation. The powder must not be swallowed dry.
Age-group administration rules: The 3 g single-dose regimen applies to adults and female adolescents 12 years of age and older. Use is not established for children below 12 years of age.
Missed-dose rules: The concept of a missed dose generally does not apply to the primary single-dose treatment course.
Special procedural conditions: Administration for cystitis is preferably carried out before bedtime and after the bladder has been emptied. Use is not recommended for patients with severe renal impairment where creatinine clearance is less than 10 ml/min.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Oral
Frequency pattern: Single-dose or intermittent (two doses separated by 24 hours).
Basis of instructions: Standardized pharmaceutical guidelines.
Use-context constraints: Administration requires specific preparation, should be done on an empty stomach, and is restricted in severe renal impairment.

Resulting Procedural Structure

Step sequence:

  • Empty the 3 g granule sachet into a glass of water (or other non-alcoholic liquid).
  • Stir until the granules are completely dissolved.
  • Consume the prepared solution immediately.
  • For cystitis, administer the dose on an empty stomach and after emptying the bladder, ideally before bedtime.

Connection to the overall use protocol: The instructions establish a precise use protocol defined by a single-dose regimen for the most common indication. This protocol mandates specific preparation steps to ensure the granules are properly administered as an oral solution, optimizing delivery and absorption. Furthermore, the instructions set clear limitations on use for specific populations, notably those with severe renal impairment.

Recent Clinical Evidence

Summary of Efficacy Trials

Research has explored how the drug is intended to function by targeting specific bacterial synthesis pathways, with studies evaluating changes in symptom presentation in individuals with infection. Clinical trials have focused on acute, uncomplicated lower urinary tract infections (UTIs) in adult women. In this indication, meta-analyses comparing single-dose fosfomycin to other oral antibiotics have generally reported similar clinical and microbiological outcomes.

Comparative Studies and Combination Therapy

Fosfomycin exhibits a broad spectrum of activity against common urinary pathogens, including E. coli and E. faecalis, and has maintained activity against certain multi-drug resistant strains. Because of its distinct mechanism of action, it is sometimes investigated in combination with other antibiotics for severe or complicated infections, although data primarily supports its use as a single agent for uncomplicated UTIs.

Safety and Tolerability Profile

Clinical research has focused on the incidence of common adverse events. Studies on the oral formulation generally describe a favorable safety profile. The most frequently reported effects in studies included mild gastrointestinal upset and temporary fatigue. Long-term surveillance data have been compiled in registry studies, examining its profile during extended use. Studies have also identified specific considerations for individuals with liver disease during treatment.

Pharmacokinetic and Dosing Information

Pharmacokinetic studies indicate that following oral administration, fosfomycin is highly concentrated in the urine for at least 24 hours. Research has investigated dosage schedules, including starting at a low dose. Studies indicate that dosage adjustments were often observed based on individual patient response and metabolic profile, with studies exploring various dosage levels.

Frequently Asked Questions (FAQ)

Common questions about Fosfomicina Doc (FAQ)

Q: Can I take aripiprazole if I'm pregnant or breastfeeding?

Official product information addresses the use of aripiprazole during pregnancy and while nursing. Exposure during the third trimester of pregnancy may cause newborns to experience extrapyramidal and/or withdrawal symptoms. For nursing mothers, official sources advise that a decision should be made regarding either discontinuing the medicine or discontinuing nursing, considering how important the medication is for the mother's health.

Q: Is aripiprazole safe to take long-term?

Regulatory documents include information from long-term clinical trials which informs the understanding of continued use of aripiprazole for certain conditions, such as maintenance treatment for schizophrenia. Official guidance indicates that maintenance treatment should be periodically reassessed by a prescriber to determine the ongoing need.

Q: Can children under 13 years old use aripiprazole?

The approved uses for aripiprazole in children and adolescents are specific to certain conditions and age groups. For instance, official labeling indicates use for irritability associated with Autistic Disorder in pediatric patients 6 years and older. Use for other conditions, such as Bipolar I Disorder and Schizophrenia, may be approved only for adolescents 10, 13, or 15 years and older, depending on the condition and official source. The medicine is generally not recommended for younger children due to a lack of sufficient safety and effectiveness data.

Q: Does aripiprazole affect my ability to drive or operate machinery?

Official sources note that this medication may cause certain side effects, such as dizziness, somnolence (drowsiness), and visual disturbances. These effects could potentially impair a person's judgment, thinking, or motor skills. Official information advises that patients should use caution until they are reasonably certain the medicine does not impair them.

How should Fosfomicina Doc be stored and disposed of?

Storage and Disposal of Fosfomicina Doc

The Fosfomycin trometamol granules for oral solution must be stored under specific regulatory conditions to maintain product stability.

Storage Requirement Condition
Temperature Limit Store at or below 30 C; Do not freeze the product.
Environmental Protection Keep the granules protected from heat, moisture, and direct sunlight.
Packaging Store the sachets in the original outer carton until preparation.
Child Safety Keep out of the sight and reach of children.

Once the granules are dissolved in water, the resulting solution must be consumed immediately; however, stability is demonstrated for 24 hours at room temperature. For disposal, unused or expired medicine must be discarded in accordance with local regulations and must not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Fosfomicina Doc found in:

A-Z Index: